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Results
Fifteen patients (median age: 55 years; 87% male) received a median 6 cycles of treatment (range: 1-33 cycles); 10 patients (67%) were surgical candidates at baseline. Twelve patients were evaluable for clinical response; 9 (60%) achieved partial response. Ten patients underwent surgery; all had complete resections and pathologic partial response. Treatment-related grade 3 adverse events included diarrhea (33%) and rash (20%). Enrollment was halted because of emerging data on expanded KRAS/NRAS mutations beyond the region we initially examined, and the potential for negative interaction with oxaliplatinbased therapy. Eight patients underwent expanded KRAS/NRAS analysis outside exon 2; no additional mutations were found.
Conclusion
KRAS/NRAS mutations outside the region tested in this study were recently shown to be associated with inferior survival on similar treatment regimens. Therefore, this trial was stopped early. This regimen remains a viable option for patients with liver-only mCRC in the KRAS/NRAS wild-type population. Enrollment criteria on future studies should include testing for the newly identified mutations.
Discussion
It was estimated that in 2015 there would be approximately 132,700 new cases ofcolorectal cancer and 49,700 deaths due to this disease [1] . While surgical resection of metastases is sometimes curative, most patients with liver metastases are not considered resectable because of the number or location of the metastases. Advances in the first-line treatment of metastatic colorectal cancer (mCRC), with increased response rates, can convert some patients with initially unresectable liver metastases to resectable, allowing for potentially curative treatment.
In the phase II OLIVIA trial, patients with liver metastases from mCRC were randomized to bevacizumab plus modified folinic acid, fluorouracil, and oxaliplatin (mFOLFOX6) or FOLFOXIRI [2] . Bevacizumab/FOLFOXIRI was associated with higher rates of response (81% vs. 62%) and resection (61% vs. 49%), and prolonged median progression-free survival (mPFS) (18.6 months vs. 11.5 months), compared with bevacizumab/mFOLFOX6. In the phase III TRIBE trial, first-line therapy with FOLFOXIRI/bevacizumab was associated with improved mPFS (12.1 months vs. 9.7 months) and response rate (65% vs. 53%) compared with FOLFIRI/bevacizumab; however, there was no difference in R0 resection rate between treatments (15% vs. 12%) [3] . A subsequent analysis showed significant improvement in median overall survival (OS) with FOLFOXIRI/bevacizumab treatment (29.8 months vs. 25.8 months) [4] . Another phase II study evaluated panitumumab with FOLFOXIRI as first-line treatment with wild-type KRAS, HRAS, NRAS, and BRAF mCRC [5] . Thirty-three patients (89%) achieved objective response. Sixteen patients (43%) underwent resection of metastatic sites, with R0 resection performed in 13 patients (35%).
Based on the potential for improved response rates, we conducted a phase II study of panitumumab plus FOLFOXIRI as first-line treatment for patients with wild-type KRAS mCRC with liver-only metastases. Patients were eligible regardless of whether they were considered surgical candidates at baseline. After the protocol was initiated, new findings were published indicating that RAS mutations outside of KRAS exon 2 are also associated with inferior survival with combination panitumumab and oxaliplatin-based therapy [6] . Enrollment was halted while patients in the study underwent expanded KRAS/NRAS analysis. Eight of the 15 patients consented to expanded analysis, with no additional mutations identified. Of the 12 patients evaluable for efficacy, 75% achieved a partial response (PR) ( Table 1) . Ten patients underwent surgery; all had complete resections that showed pathologic PR. No significant safety signals were seen; the mostcommon treatment-related adverse events (all grades) were rash (80%), diarrhea (60%), fatigue (53%), and nausea (53%). Despite early closure of the study, this regimen is a viable option for patients with liver-only mCRC. 
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Patient Characteristics
Number of patients, male
13
Number of patients, female Response assessment PD
Response assessment OTHER 
Investigator's Assessment
Active and should be pursued further
Discussion
In the phase II OLIVIA trial, patients with liver metastases from mCRC were randomized to bevacizumab plus modified folinic acid, fluorouracil, and oxaliplatin (mFOLFOX6) or FOLFOXIRI [2] . Bevacizumab/FOLFOXIRI was associated with higher rates of response (81% vs. 62%) and resection (61% vs. 49%), and prolonged median progression-free survival (mPFS) (18.6 months vs. 11.5 months), compared with bevacizumab/mFOLFOX6. In the phase III TRIBE trial, first-line therapy with FOLFOXIRI/bevacizumab was associated with improved mPFS (12.1 months vs. 9.7 months) and response rate (65% vs. 53%) compared with FOLFIRI/bevacizumab; however, there was no difference in R0 resection rate between treatments (15% vs. 12%) [3] . A subsequent analysis showed significant improvement in median overall survival (OS) with FOLFOXIRI/ bevacizumab treatment (29.8 months vs. 25.8 months) [4] . Another phase II study evaluated panitumumab with FOLFOXIRI as first-line treatment with wild-type KRAS, HRAS, NRAS, and BRAF mCRC [5] .Thirty-three patients (89%) achieved objective response. Sixteen patients (43%) underwent resection of metastatic sites, with R0 resection performed in 13 patients (35%).
Based on the potential for improved response rates, we conducted a phase II study of panitumumab plus FOLFOXIRI as first-line treatment for patients with wild-type KRAS mCRC with liver-only metastases. Patients were eligible regardless of whether they were considered surgical candidates at baseline. After the protocol was initiated, new findings were published indicating that RAS mutations outside of KRAS exon 2 are also associated with inferior survival with combination panitumumab and oxaliplatin-based therapy [6] . Enrollment was halted while patients in the study underwent expanded KRAS/NRAS analysis. Figures 1 and 2 present PFS and OS data from our study. Eight of the 15 patients consented to expanded analysis, with no additional mutations identified. Of the 12 patients evaluable for efficacy, 75% achieved a partial response (PR) ( Table 1) . Ten patients underwent surgery; all had complete resections that showed pathologic PR. No significant safety signals were seen; the most common treatment-related adverse events (all grades) were rash (80%), diarrhea (60%), fatigue (53%), and nausea (53%) ( Table 2 ). Despite early closure of the study, this regimen is a viable option for patients with liver-only mCRC. 
